204 related articles for article (PubMed ID: 30422368)
1. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
2. Phase I, multicenter, randomized, open-label study evaluating the pharmacokinetics and safety profile of repeated once-daily doses of intravenous esomeprazole in children 0 to 17 years of age.
Sandström M; Davidson G; Tolia V; Sullivan JE; Långström G; Lundborg P; Brown K
Clin Ther; 2012 Aug; 34(8):1828-38. PubMed ID: 22832034
[TBL] [Abstract][Full Text] [Related]
3. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
[TBL] [Abstract][Full Text] [Related]
4. Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Kagami T; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Digestion; 2015; 91(4):277-85. PubMed ID: 25924819
[TBL] [Abstract][Full Text] [Related]
5. The pharmacokinetics, pharmacodynamics and safety of oral doses of ilaprazole 10, 20 and 40 mg and esomeprazole 40 mg in healthy subjects: a randomised, open-label crossover study.
Shin JS; Lee JY; Cho KH; Park HL; Kukulka M; Wu JT; Kim DY; Park SH
Aliment Pharmacol Ther; 2014 Sep; 40(5):548-61. PubMed ID: 25041486
[TBL] [Abstract][Full Text] [Related]
6. Esomeprazole FDA Approval in Children With GERD: Exposure-Matching and Exposure-Response.
Earp JC; Mehrotra N; Peters KE; Fiorentino RP; Griebel D; Lee SC; Mulberg A; Röhss K; Sandström M; Taylor A; Tornøe CW; Wynn EL; Van der Walt JS; Garnett C
J Pediatr Gastroenterol Nutr; 2017 Sep; 65(3):272-277. PubMed ID: 27875488
[TBL] [Abstract][Full Text] [Related]
7. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
[TBL] [Abstract][Full Text] [Related]
8. Early effects of oral administration of esomeprazole and omeprazole on the intragastric pH.
Iida H; Inamori M; Okuno K; Sekino Y; Sakai E; Okubo H; Higurashi T; Endo H; Hosono K; Yoneda M; Koide T; Takahashi H; Goto A; Kubota K; Saito S; Maeda S; Nakajima A; Gotoh E
Hepatogastroenterology; 2015; 62(138):493-6. PubMed ID: 25916088
[TBL] [Abstract][Full Text] [Related]
9. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data.
Schwab M; Klotz U; Hofmann U; Schaeffeler E; Leodolter A; Malfertheiner P; Treiber G
Clin Pharmacol Ther; 2005 Dec; 78(6):627-34. PubMed ID: 16338278
[TBL] [Abstract][Full Text] [Related]
10. A 6-month, multicenter, open-label study of fixed dose naproxen/esomeprazole in adolescent patients with juvenile idiopathic arthritis.
Lovell DJ; Dare JA; Francis-Sedlak M; Ball J; LaMoreaux BD; Von Scheven E; Reinhardt A; Jerath R; Alpan O; Gupta R; Goldsmith D; Zeft A; Naddaf H; Gottlieb B; Jung L; Holt RJ
Pediatr Rheumatol Online J; 2018 Jun; 16(1):41. PubMed ID: 29941047
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26422093
[TBL] [Abstract][Full Text] [Related]
12. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
13. Safety and Tolerability of Esomeprazole in Children With Gastroesophageal Reflux Disease.
Gilger MA; Tolia V; Vandenplas Y; Youssef NN; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S16-23. PubMed ID: 26121345
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the effects of esomeprazole 40 mg, rabeprazole 20 mg, lansoprazole 30 mg, and pantoprazole 40 mg on intragastrıc pH in extensive metabolizer patients with gastroesophageal reflux disease.
Çelebi A; Aydın D; Kocaman O; Konduk BT; Şentürk Ö; Hülagü S
Turk J Gastroenterol; 2016 Sep; 27(5):408-414. PubMed ID: 27782887
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.
Yang H; Li J; Zhao Q; Li J; Shen K; Yang X; Jiang J; Hu P; Qian J
J Gastroenterol Hepatol; 2013 Dec; 28(12):1823-8. PubMed ID: 23800161
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease.
Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S2-8. PubMed ID: 26422094
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Acid-suppressive Effects of Esomeprazole in Infants 1-24 Months Old With Symptoms of Gastroesophageal Reflux Disease.
Omari T; Davidson G; Bondarov P; Nauclér E; Nilsson C; Lundborg P
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S2-8. PubMed ID: 26121346
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes.
Nagase M; Shimada H; Nii M; Ueda S; Higashimori M; Ichikawa K; Zhang L; Zhou L; Chen Y; Zhou D; Dunyak J; Al-Huniti N
J Clin Pharm Ther; 2020 Oct; 45(5):1030-1038. PubMed ID: 32227647
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study.
Zhao J; Li J; Hamer-Maansson JE; Andersson T; Fulmer R; Illueca M; Lundborg P
Clin Ther; 2006 Nov; 28(11):1868-76. PubMed ID: 17213007
[TBL] [Abstract][Full Text] [Related]
20. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control.
Wang H; Shao F; Liu X; Xu W; Ou N; Qin X; Liu F; Hou X; Hu H; Jiang J
Br J Clin Pharmacol; 2019 Nov; 85(11):2547-2558. PubMed ID: 31332820
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
